Nucala FDA Approval History
Last updated by Judith Stewart, BPharm on Aug 6, 2021.
FDA Approved: Yes (First approved November 4, 2015)
Brand name: Nucala
Generic name: mepolizumab
Dosage form: Injection
Treatment for: Eosinophilic Asthma; Chronic Rhinosinusitis with Nasal Polyps; Eosinophilic Granulomatosis with Polyangiitis; Hypereosinophilic Syndrome
Nucala (mepolizumab) is an interleukin-5 antagonist monoclonal antibody (IgG1 kappa) used for the treatment of with severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), and hypereosinophilic syndrome (HES).
- Nucala is indicated for:
- Add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype.
- Add-on maintenance treatment of adult patients 18 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP).
- The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
- The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non-hematologic secondary cause.
Limitations of use: Not for relief of acute bronchospasm or status asthmaticus.
- Nucala is administered via subcutaneous injection once every 4 weeks.
- Nucala can cause serious adverse reactions including hypersensitivity reactions and herpes zoster infections.
- Common adverse reactions include: headache, injection site reactions (pain, redness, swelling, itching, or a burning feeling at the injection site), back pain, and tiredness (fatigue). Mouth/throat pain and joint pain have been reported with CRSwNP.
Development timeline for Nucala
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.